抗幽合剂联合四联疗法治疗慢性胃炎合并幽门螺杆菌阳性患者25例临床观察  

Clinical Observation on Kangyou Heji( 抗幽合剂)Combined with Quadri-combination Therapy Treating 25 Patients with Chronic Gastritis with Positive Helicobacter Pylori

作　　者：汪楠[1] 王垂杰[2] 李玉锋[2] 

机构地区：[1]辽宁中医药大学 [2]辽宁中医药大学附属医院

出　　处：《中医杂志》2016年第2期136-139,共4页Journal of Traditional Chinese Medicine

基　　金：国家科技重大专项(2010ZX09401-304);2012年辽宁省中医药临床学(专科)能力建设项目(2012-lnzyxzk-03)

摘　　要：目的评价抗幽合剂联合四联疗法对慢性胃炎合并幽门螺杆菌(Hp)阳性患者Hp根除率的影响。方法将75例慢性胃炎合并Hp阳性患者随机分为对照组、辨证组、抗幽组各25例。对照组给予西药四联疗法(奥美拉唑肠溶胶囊每次20 mg,阿莫西林胶囊每次1g或克拉霉素胶囊每次500 mg,左氧氟沙星片每次200 mg,枸橼酸铋钾冲剂每次220 mg口服,均每日2次);辨证组给予西药四联疗法加中医辨证论治汤剂口服,每日1剂,每日2次;抗幽组给予西药四联疗法加抗幽合剂口服,每日1剂,每日2次。各组均治疗14天。分别于治疗前后评价各组患者主要症状评分、中医脾胃疾病患者报告临床结局(PRO)量表评分,以及血、尿、便常规和肝功能、肾功能等安全性指标,并于停药30天后检测各组患者Hp转阴情况。结果对照组Hp转阴17例、Hp根除率为68.0%,抗幽组为23例、95.8%,辨证组为19例、76.0%,抗幽组与辨证组Hp根除率均高于对照组(P<0.01)。治疗后各组患者主要症状积分与PRO量表各症状、维度、总分均较治疗前显著明显降低(P<0.05或P<0.01),治疗后各组间比较差异无统计学意义(P>0.05)。治疗前后各组安全性指标比较差异无统计学意义(P>0.05)。结论抗幽合剂联合西药四联疗法能够提高慢性胃炎合并Hp阳性患者的Hp根除率,并能安全有效地改善患者临床症状。Objective To evaluate the effects of Kangyou Heji（ 抗幽合剂） combined with quadri-combination therapy on helicobacter-pylori（ Hp） eradication rate in patients with chronic gastritis combined with positive Hp.Methods Seventy-five patients with chronic gastritis with positive Hp were randomly divided into a control group,a syndrome differentiation group,and an anti-Hp group（ 25 cases in each group）. The control group was given the quadruple therapy（ omeprazole enteric capsules 20 mg each time,amoxil capsules 1 g each time or clarithromycin capsules 500 mg each time,levofloxacin tablets 200 mg each time,bismuth potassium citrate electuary 220 mg each time） twice a day. The syndrome differentiation group was given the quadruple therapy combined with Chinese medical syndrome differentiation decoction,one dose a day,take half dose each and twice a day. The anti-Hp group was given the quadruple therapy combined with Kangyou Heji one dose a day,take half dose each and twice a day. Each group was treated for 14 days. The researchers respectively evaluated The main symptom scores,scores of patientreported outcome（ PRO） in Chinese medicine for patients with spleen and stomach disease,and safety indexes such as routine of blood,urine,and stool,and liver and renal function of each group before and after the treatments. On the 30 th day after stopping medication,Hp turning-negative rate of patients was tested in each group. Results After treatment,result of Hp test was negative in 17 cases in the control group,with the rate of Hp eradication of68. 0%. And there were 23 cases（ 95. 8%） with Hp negative in the anti-Hp group and 19 cases（ 76. 0%） in the syndrome differentiation group. The rates of Hp eradication in the anti-Hp group and in the syndrome differentiation group were much higher than that in the control group（ P〈0. 01）. After treatment,the main symptom scores,as well as each symptom score,dimensionality,and total scores in PRO scale of patients in each group significantly decreased

关 键 词：慢性胃炎 幽门螺杆菌 抗幽合剂 四联疗法 

分 类 号：R573.3[医药卫生—消化系统]